Indee Labs

Hydropore™

2023

Research, Concept, Development, Electronics

 

Indee Labs: Hydropore™

A simple, scalable, and efficient way to accelerate the discovery, development, and manufacturing of engineered cell therapies

Hydropore™ is a simple, scalable, and efficient way to accelerate the discovery, development, and manufacturing of engineered cell therapies such as T-cell immunotherapies. This novel, non-viral technology utilises the power of microfluidic vortex shedding (µVS) to rapidly deliver small molecules, nucleic acids, proteins, and gene-editing complexes to immune cells in a matter of seconds, yielding millions to billions of high-quality cells with negligible impact to cell viability and function. Hydropore™ bypasses the challenges and limitations of viral transduction and traditional transfection via electroporation, allowing companies to accelerate their research goals from discovery to manufacturing. Our working relationship with Indee Labs commenced in 2018 when D+I was approached to drive the development (Industrial design, mechanical engineering + electronics design) through an ISO 13485 compliant process, as well as to enhance the usability + styling of this highly complex system. Indee Labs are actively working towards a commercialised, fully certified and calibrated device capable of processing a billion cells simultaneously. The ultimate aim is to accelerate the development of cell and gene therapies to treat cancers, graft-versus-host disease, and many other indications.

Research Use Only (RUO)

Complete Product Development: Industrial Design, Mechanical Engineering + Electronics Design

 
 

The future of cell therapies.

Indee Labs is a biotechnology startup working with the best to develop scalable, high-yield cell engineering therapies.

Hydropore™ (µVS Delivery System™) is currently available for Research Use Only (RUO) and is verified or in development for immune cells including T cells, Tregs and TILs, PBMCs, Natural Killer (NK) cells, cell models such as HEK293Ts & Jurkats, and more. This platform is also validated for the delivery of CRISPR-Cas9 and mRNA to donor immune cells, specifically in primary human activated CD3+ T cells. The team at Indee Labs has demonstrated revolutionary improvements over existing methods including scalability, high yield, negligible perturbation of the immune cell state along with rapid processing of research and clinical-scale samples with a simple workflow utilising the small benchtop system.

We’re looking to ultimately manufacture these life-changing therapeutics for tens of millions of people every year.
- Ryan Pawell, CEO

To learn more, visit www.indeelabs.com

 
 

VIEW MORE PROJECTS